ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027

April 22, 2026 - 01:31

LYON, France, April 21, 2026 -- Adocia, a clinical-stage biopharmaceutical company developing treatments for diabetes and obesity, has announced a strategic financial agreement with Vester Finance. The deal involves a shareholder loan that will be repayable through the issuance of new company shares. This arrangement provides Adocia with critical capital while offering flexibility, as the company retains an option to repay the loan in cash under specific, predefined conditions.

This financing is a pivotal development for Adocia, directly addressing its near-term capital requirements. The influx of funds is projected to significantly extend the company's operational cash runway, ensuring financial stability through the beginning of the second quarter of 2027. This extended timeline provides Adocia with a substantial window to advance its key research and development programs without the immediate pressure of seeking additional financing.

The agreement underscores a vote of confidence from a key shareholder, Vester Finance, in Adocia's long-term strategy and pipeline potential. By opting for a structure repayable in shares, the agreement aims to minimize immediate cash outflow, allowing Adocia to allocate more resources directly to its clinical trials and scientific endeavors. This move is designed to bolster the company's efforts to bring innovative therapeutic solutions for metabolic diseases through the development pipeline and closer to patients in need.